Michon-Colin, Arthur http://orcid.org/0000-0002-8678-3733
Bouderlique, Elise
Prié, Dominique
Maruani, Gérard
Nevoux, Jérôme
Briot, Karine
Courbebaisse, Marie
Article History
Received: 13 October 2023
Accepted: 19 November 2023
First Online: 9 January 2024
Declarations
:
: KB: fees for conference organization, board member of the XLH registry sponsored by KYOWA KIRIN PHARMA and participation in burosumab clinical trials conducted by KYOWA KIRIN PHARMA. GM: fees for moderating a round table during a conference organized by KYOWA KIRIN PHARMA. AMC, EB, DP, JN, and MC have no competing interests to declare that are relevant to the content of this article.
: The patient has been informed and has not objected to the use of this data for this publication, which has been collected in compliance with the requirements of the CNIL (Commission Nationale de l'Informatique et des Libertés). Under these conditions, recourse to an ethics commission is optional under French legislation. Signed consent to participate in research was obtained from our Physiology Department.